Leheny A. Rachel 4

4 · CalciMedica, Inc. · Filed Jan 25, 2024

Form 4

Period: 2024-01-23

DirectorCHIEF EXECUTIVE OFFICER10% Owner

Transactions

Award
Warrant
2024-01-23$0.13/sh+45,543$5,693→ 45,543 total
Exercise: $7.15From: 2024-01-23Exp: 2026-12-31→ Common Stock (45,543 underlying)
Award
Warrant
2024-01-23$0.13/sh+45,543$5,693→ 45,543 total
Exercise: $5.36From: 2024-01-23Exp: 2024-12-31→ Common Stock (45,543 underlying)
Award
Common Stock
2024-01-23$4.27/sh+91,086$388,618→ 109,926 total

Holdings

Footnotes (4)

[F1]The securities were acquired from the Issuer pursuant to a Securities Purchase Agreement dated January 19, 2024, with a closing date of January 23, 2024. The Securities Purchase Agreement and the issuance of the securities thereunder was approved by an independent committee of the Issuer's Board of Directors.
[F2]The Reporting Person, a co-founder and managing director of Valence Investments SPV IV, LLC ("Valence IV"), Valence Investments SPV V, LLC ("Valence V") and Valence Investments SPV VI, LLC (Valence VI), may be deemed to beneficially own the securities held by Valence IV, Valence V and Valence VI (the "Valence Securities"). The Reporting Person disclaims beneficial ownership of the Valence Securities except to the extent of her pecuniary interest therein.
[F3]The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2024, and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's Phase 2b clinical trial in patients with acute pancreatitis but not thereafter.
[F4]The warrant may be exercised on or after January 23, 2024, and on or prior to the earlier of (i) 5:00 p.m. (New York City time) on December 31, 2026 and (ii) thirty (30) days following the Issuer's public disclosure of topline results from the Issuer's planned Phase 2 clinical trial in patients with acute kidney injury but not thereafter.

Documents

1 file